The concurrent inhibition of EZH2 and DNMT1, but not individual agents, significantly boosts T cell infiltration, slows down tumor progression, and enhances the therapeutic response to the PD-L1 checkpoint blockade in tumor-bearing mice. Here, EZH2 is linked to neoplasm.